Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

The vaccine contains chemically inactivated whole poliovirus particles of the three serotypes. After injection, the viral antigens are processed by the immune system, prompting B‑cell activation and the production of neutralizing antibodies that block future infection without the virus replicating in the body.

The dosing regimen for Imovax Polio is determined by the prescribing healthcare professional based on age, immunization history and local guidelines. The prescriber decides the number of doses, interval between doses and the route of administration.

Safety data for Imovax Polio in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits and risks before vaccinating pregnant or breastfeeding individuals, and discuss any concerns with the patient.

To order Imovax Polio, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Imovax Polio is an inactivated polio vaccine (IPV) that does not contain live virus, unlike oral polio vaccine (OPV). IPV carries no risk of vaccine‑derived poliovirus and is preferred in settings where eradication is a priority, while OPV is easier to administer orally but can rarely revert to neurovirulent forms.

Imovax Polio must be stored refrigerated at 2 °C to 8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use the product if the cold‑chain has been broken.

The vaccine is supplied as an injectable solution and is given by a trained healthcare professional via intramuscular or subcutaneous injection, typically in the deltoid or anterolateral thigh muscle, following aseptic technique.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, seizures, persistent high fever, severe hypotension and other neurological complications. Immediate medical attention is required if any of these occur after vaccination.

Individuals with a known severe allergy to any component of the vaccine, those who have experienced a previous serious reaction to an inactivated polio vaccine, and persons with acute moderate or severe illness should defer vaccination until the condition resolves.